Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment

Archives of Medical Research

Volumn 35, Issue 2, 2004, Pages 168-171

  Moreno, Julia ^a,f   Belmont, Aurora ^b   Jaimes, Orlando ^a   Santos, José A ^a   López, Guadalupe ^a   Campos, María G ^c   Amancio, Octavio ^d   Pérez, Patricia ^e   Heinze, Gerardo ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d Hospital de Mexico   (Mexico)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^f INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Carbamazepine; Carbamazepine 10,11 epoxide; Epileptic; Pharmacokinetic

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DRUG METABOLITE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM CARE; MEXICO; POPULATION RESEARCH;

EID: 1542298987     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2003.09.016     Document Type: Article

References (35)

1. Rubio D.F. Generalidades y clasificación de la epilepsia. Feria V.A., Martínez M.D., Rubio D.F. Epilepsia: un enfoque multidisciplinario. 1986;Trillas, México.
2. Morrell M.J. Antiepileptic drugs, seizures, and birth defects. Int Pediatr. 10:(Suppl):1995;58-65.
3. Morrell M.J. Hormones and epilepsy through the lifetime. Epilepsia. 33:(Suppl):1992;S49-S61.
4. Murialdo G., Galimberti C.A., Magri F., Sampaolo P., Copello F., Gianelli M.V., Gazzerro E., Rollero A., Deagatone C., Manni R., Ferrari E., Polleri A., Tartara A. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest. 20:1997;519-526.
5. Klein P., Herzog A.G. Hormonal effects on epilepsy in women. Epilepsia. 39:(Suppl 8):1998;S9-S16.
6. Shenfield G.M. Oral contraceptives. Are drug interactions of clinical significance? Drug Saf. 9:1993;21-37.
7. Mattson R.H., Cramer J.A., Darney P.D., Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA. 256:1986;238-240.
8. Krauss G.L., Brandt J., Campbell M., Plate C., Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology. 46:1996;1534-1539.
9. Perucca E., Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet. 7:1982;336-352.
10. Yerby M.S. Problems and management of the pregnant woman with epilepsy. Epilepsia. 28:(Suppl):1987;S29-S36.
11. Bernus I., Hooper W.D., Dickinson R.G., Eadie M.J. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy. Epilepsy Res. 21:(1):1995;65-75.
12. Malone F.D., D'Alton M.E. Treatment of epilepsy in pregnancy. Drugs. 57:(4):1999;535-544.
13. Lindhout D., Omtzigt J.G. Pregnancy and the risk of teratogenicity. Epilepsia. 33:(Suppl 4):1992;S41-S48.
14. Bennett G.D., Amore B.M., Finnell R.H., Wlodarczyk B., Kalhorn T.F., Skiles G.L., Nelson S.D., Slattery J.T. Teratogenicity of carbamazepine 10,11-epoxide and oxcarbazepine in the SWV mouse. J Pharmacol Exp Ther. 279:(3):1996 Dec;1237-1242.
15. Llewellyn A., Stowe Z.N. Psychotropic medications in lactation. J Clin Psychiatry. 59:(Suppl 2):1998;41-52.
16. Chisholm C.A., Kuller J.A. A guide to the safety of CNS-active agents during breastfeeding. Drug Safety Concepts. 17:(2):1997;127-142.
17. Ballenger J.C., Post R.M. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 137:1980;782-790.
18. Post R.M., Uhde T.W., Ballenger J.C., Squillace K.M. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry. 140:1983;1602-1604.
19. DeVane L. Fundamentals of monitoring psychoactive drug therapy in drug therapy for mood disorders (E) intraclass comparisons of antidepressants and mood stabilizers. 1990;Williams & Wilkins, Baltimore, MD, USA. pp. 128-130.
20. Yung H., Milan R.C., Girard M.E., León F., Montoya M.A. Bioequivalence study of carbamazepine tablets: in vitro/in vivo correlation. Int J Pharmaceutics. 152:1997;37-44.
21. Moreno J., Jaimes O., Dorantes A.M., Nieves E., López G., Belmont A., Heinze G. Comparación de análisis inmunoenzimáticoy cromatografía de líquidos de alta eficiencia (EMIT y HPLC) para la medición de carbamacepina en muestras séricas. Salud Mental. 24:(5):2001;12-16.
22. Gibaldi M., Perrier D. 2nd ed. Pharmacokinetics. Vol. 15:1982;Marcel Dekker, New York.
23. Leppik I.E., Pascual-Leone A., Dhura A. Oral loading with carbamazepine: pilot study. Epilepsia. 29:1988;699-700.
24. Goodman & Gilman. Las bases farmacológicas de la terapéutica. 1996;McGraw Hill Interamericana Editores, S.A. de C.V. México, D.F.
25. Barlets H. Rational usage of therapeutic drugs monitoring in antiepileptic treatment. Eur J Pediatr. 133:1980;193-199.
26. Callaghan N., Kenny R.A., O'Neill B., Crowley M., Goggin T.A. A prospective study between carbamazepine, phenytoin, and sodium valproate as monotherapy in previous untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry. 48:1985;639-644.
27. Ramsey R.E., Wilder B.J., Berger J.R., Bruni J. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology. 33:1983;904-910.
28. Choonara I.A., Anders R. Therapeutic drug monitoring of anticonvulsant state of the art. Clin Pharmacokinet. 18:(4):1990;318-328.
29. Cohen H., Howland M., Luciano D.J., Rubin R.N., Kutt H., Hoffman R.S., Leung L.K.H., Devinsky O., Goldfrank L.R. Feasibility and pharmacokinetics of carbamazepine oral loading doses. Am J Health Syst Pharm. 55:(11):1998;1134- 1140.
30. Bernus I., Dickson R. Dose-dependent metabolism of carbamazepine in humans. Epilepsy Res. 24:1996;163-172.
31. Air C. The epilepsies, a critical review. 1994;Raven, New York.
32. Tomson T., Almkvist O., Nilsson B.Y. Carbamazepine 10,11-epoxide in epilepsy: a pilot study. Arch Neurol. 47:1990;888-892.
33. Kanner A.M., Hudson P., Hasegawa H.A. Practical use of single-dose pharmacokinetic studies of carbamazepine. Epilepsia. 31:1990;602.
34. Levy R.H., Bradley M.K. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry. 49:(Suppl 4):1988;58-61.
35. Brodie M.J., Forrest G., Rappeport W.G. Carbamazepine 10,11-epoxide concentrations in epileptics on carbamazepine alone and combination with other anticonvulsants. Br J Clin Pharmacol. 16:1983;747-750.